The MST of the Tf-ELE/CTX@BLIP group was 33 days, high by 6.5% and 10.0% compared with that of the ELE/CTX@BLIP and Tf-ELE/CTX@LIP groups, indicating that Tf and CMP synergistically contributed to the anti-glioma effect of Tf-ELE/CTX@BLIP, which can be attributed to brain accumulation of the drugs and homologous gliomas targeting. The gene discussed is TF; the disease is glioma.